| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hip Prosthesis | 76 | 2023 | 537 | 12.980 |
Why?
|
| Arthroplasty, Replacement, Hip | 77 | 2023 | 806 | 11.280 |
Why?
|
| Prosthesis Failure | 70 | 2023 | 520 | 8.970 |
Why?
|
| Metals | 37 | 2022 | 139 | 6.080 |
Why?
|
| Cobalt | 30 | 2023 | 109 | 4.740 |
Why?
|
| Prosthesis Design | 61 | 2023 | 487 | 4.690 |
Why?
|
| Metal-on-Metal Joint Prostheses | 16 | 2022 | 49 | 4.370 |
Why?
|
| Chromium | 23 | 2020 | 86 | 4.140 |
Why?
|
| Polyethylene | 24 | 2021 | 124 | 3.850 |
Why?
|
| Titanium | 27 | 2020 | 172 | 3.770 |
Why?
|
| Arthroplasty, Replacement, Knee | 33 | 2021 | 633 | 3.590 |
Why?
|
| Osteolysis | 19 | 2021 | 140 | 2.490 |
Why?
|
| Foreign-Body Reaction | 10 | 2017 | 26 | 2.420 |
Why?
|
| Corrosion | 29 | 2023 | 125 | 2.350 |
Why?
|
| Orthopedics | 11 | 2021 | 111 | 2.320 |
Why?
|
| Prostheses and Implants | 13 | 2021 | 154 | 2.120 |
Why?
|
| Biocompatible Materials | 11 | 2013 | 91 | 2.050 |
Why?
|
| Humans | 159 | 2023 | 27193 | 1.960 |
Why?
|
| Device Removal | 15 | 2021 | 85 | 1.790 |
Why?
|
| Chromium Alloys | 11 | 2023 | 44 | 1.660 |
Why?
|
| Knee Prosthesis | 14 | 2021 | 224 | 1.620 |
Why?
|
| Alloys | 17 | 2018 | 95 | 1.480 |
Why?
|
| Hip Joint | 9 | 2017 | 545 | 1.390 |
Why?
|
| Reoperation | 32 | 2021 | 923 | 1.380 |
Why?
|
| Arthroplasty, Replacement | 9 | 2021 | 151 | 1.380 |
Why?
|
| Hypersensitivity | 9 | 2021 | 47 | 1.270 |
Why?
|
| Societies, Medical | 3 | 2021 | 123 | 1.210 |
Why?
|
| Lymphocyte Activation | 6 | 2020 | 84 | 1.180 |
Why?
|
| Male | 73 | 2022 | 14847 | 1.170 |
Why?
|
| Postoperative Complications | 12 | 2021 | 928 | 1.130 |
Why?
|
| Risk Assessment | 13 | 2021 | 631 | 1.130 |
Why?
|
| Joint Prosthesis | 7 | 2019 | 87 | 1.090 |
Why?
|
| Middle Aged | 56 | 2021 | 9030 | 1.070 |
Why?
|
| Female | 65 | 2021 | 15286 | 1.060 |
Why?
|
| Materials Testing | 12 | 2021 | 127 | 1.050 |
Why?
|
| Venous Thromboembolism | 4 | 2012 | 37 | 0.920 |
Why?
|
| Aged | 55 | 2021 | 9075 | 0.920 |
Why?
|
| Surface Properties | 21 | 2021 | 132 | 0.900 |
Why?
|
| Biomedical Research | 3 | 2009 | 58 | 0.850 |
Why?
|
| Osteoarthritis, Hip | 9 | 2014 | 105 | 0.800 |
Why?
|
| Orthopedic Procedures | 5 | 2020 | 308 | 0.800 |
Why?
|
| Models, Theoretical | 2 | 2020 | 84 | 0.790 |
Why?
|
| Musculoskeletal Diseases | 3 | 2013 | 44 | 0.790 |
Why?
|
| Adult | 39 | 2021 | 7910 | 0.760 |
Why?
|
| Algorithms | 4 | 2021 | 351 | 0.740 |
Why?
|
| Ions | 8 | 2014 | 53 | 0.720 |
Why?
|
| Computer-Assisted Instruction | 1 | 2021 | 20 | 0.700 |
Why?
|
| Consensus | 1 | 2021 | 91 | 0.690 |
Why?
|
| Equipment Failure Analysis | 15 | 2017 | 98 | 0.690 |
Why?
|
| Lymphocytes | 6 | 2021 | 59 | 0.670 |
Why?
|
| Gait | 2 | 2020 | 411 | 0.640 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2009 | 5 | 0.610 |
Why?
|
| Joint Diseases | 2 | 2012 | 114 | 0.610 |
Why?
|
| Biomarkers | 10 | 2021 | 558 | 0.610 |
Why?
|
| Surgeons | 1 | 2020 | 88 | 0.600 |
Why?
|
| Tantalum | 3 | 2007 | 27 | 0.590 |
Why?
|
| Stress, Mechanical | 10 | 2020 | 157 | 0.580 |
Why?
|
| Particle Size | 10 | 2014 | 50 | 0.580 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 1135 | 0.560 |
Why?
|
| Aged, 80 and over | 30 | 2021 | 4826 | 0.560 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2012 | 195 | 0.540 |
Why?
|
| Prospective Studies | 11 | 2020 | 1777 | 0.530 |
Why?
|
| Ceramics | 6 | 2015 | 20 | 0.520 |
Why?
|
| Treatment Outcome | 14 | 2017 | 3542 | 0.510 |
Why?
|
| Synovial Fluid | 7 | 2018 | 92 | 0.500 |
Why?
|
| Acetabulum | 7 | 2012 | 229 | 0.490 |
Why?
|
| Practice Guidelines as Topic | 3 | 2012 | 260 | 0.480 |
Why?
|
| Nickel | 7 | 2019 | 28 | 0.470 |
Why?
|
| Prosthesis-Related Infections | 4 | 2015 | 184 | 0.470 |
Why?
|
| Retrospective Studies | 13 | 2021 | 3565 | 0.460 |
Why?
|
| Femur | 8 | 2019 | 378 | 0.450 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2012 | 106 | 0.450 |
Why?
|
| Intervertebral Disc | 3 | 2017 | 120 | 0.450 |
Why?
|
| Foreign Bodies | 3 | 2020 | 26 | 0.440 |
Why?
|
| Inflammation | 6 | 2021 | 274 | 0.430 |
Why?
|
| Cervical Vertebrae | 1 | 2017 | 289 | 0.420 |
Why?
|
| Cost of Illness | 1 | 2013 | 50 | 0.420 |
Why?
|
| United States | 9 | 2021 | 2056 | 0.420 |
Why?
|
| Animals | 15 | 2021 | 3645 | 0.410 |
Why?
|
| Guided Tissue Regeneration | 2 | 2018 | 11 | 0.410 |
Why?
|
| Total Disc Replacement | 1 | 2012 | 14 | 0.390 |
Why?
|
| Cysts | 1 | 2012 | 15 | 0.380 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 4 | 2021 | 15 | 0.380 |
Why?
|
| Health Promotion | 1 | 2013 | 144 | 0.380 |
Why?
|
| Biomechanical Phenomena | 8 | 2020 | 641 | 0.380 |
Why?
|
| Osteoblasts | 5 | 2014 | 57 | 0.370 |
Why?
|
| Synovial Membrane | 3 | 2008 | 54 | 0.370 |
Why?
|
| Polyethylenes | 4 | 2020 | 39 | 0.360 |
Why?
|
| Cytokines | 7 | 2019 | 233 | 0.360 |
Why?
|
| Macrophages | 7 | 2021 | 106 | 0.350 |
Why?
|
| Follow-Up Studies | 14 | 2021 | 1803 | 0.350 |
Why?
|
| Vitallium | 4 | 2023 | 27 | 0.340 |
Why?
|
| Chronic Pain | 1 | 2012 | 135 | 0.340 |
Why?
|
| Tibia | 6 | 2020 | 246 | 0.340 |
Why?
|
| Inflammasomes | 4 | 2021 | 17 | 0.330 |
Why?
|
| Risk Factors | 10 | 2019 | 2330 | 0.330 |
Why?
|
| B-Lymphocytes | 1 | 2010 | 56 | 0.330 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 99 | 0.320 |
Why?
|
| Health Education | 1 | 2009 | 46 | 0.320 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 693 | 0.320 |
Why?
|
| Health Services Research | 1 | 2009 | 38 | 0.310 |
Why?
|
| Time Factors | 13 | 2020 | 1447 | 0.300 |
Why?
|
| Rheumatology | 1 | 2009 | 85 | 0.300 |
Why?
|
| Models, Biological | 4 | 2017 | 320 | 0.290 |
Why?
|
| Molybdenum | 5 | 2021 | 21 | 0.290 |
Why?
|
| Radiography | 9 | 2018 | 623 | 0.290 |
Why?
|
| Cross-Linking Reagents | 1 | 2007 | 13 | 0.290 |
Why?
|
| Glycoproteins | 1 | 2007 | 49 | 0.280 |
Why?
|
| Fibroblasts | 4 | 2008 | 57 | 0.270 |
Why?
|
| Caspase 1 | 4 | 2021 | 16 | 0.270 |
Why?
|
| Biomedical Technology | 1 | 2006 | 6 | 0.260 |
Why?
|
| Europium | 2 | 2020 | 5 | 0.260 |
Why?
|
| Stearates | 2 | 2020 | 5 | 0.260 |
Why?
|
| Conflict of Interest | 1 | 2006 | 13 | 0.260 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2016 | 34 | 0.260 |
Why?
|
| Interprofessional Relations | 1 | 2006 | 34 | 0.260 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 478 | 0.250 |
Why?
|
| Evidence-Based Medicine | 4 | 2012 | 162 | 0.250 |
Why?
|
| Weight-Bearing | 5 | 2011 | 157 | 0.240 |
Why?
|
| Cell Transplantation | 1 | 2005 | 21 | 0.240 |
Why?
|
| Metal Nanoparticles | 2 | 2018 | 9 | 0.240 |
Why?
|
| Environmental Monitoring | 1 | 2004 | 11 | 0.230 |
Why?
|
| Hypersensitivity, Delayed | 2 | 2019 | 10 | 0.230 |
Why?
|
| Signal Transduction | 4 | 2019 | 446 | 0.230 |
Why?
|
| Spleen | 1 | 2004 | 32 | 0.230 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 1367 | 0.230 |
Why?
|
| Spinal Diseases | 1 | 2006 | 113 | 0.230 |
Why?
|
| Metal Ceramic Alloys | 1 | 2004 | 3 | 0.220 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 352 | 0.220 |
Why?
|
| Monocytes | 6 | 2016 | 61 | 0.220 |
Why?
|
| Liver | 1 | 2004 | 148 | 0.210 |
Why?
|
| Elective Surgical Procedures | 3 | 2012 | 37 | 0.210 |
Why?
|
| Biofilms | 1 | 2003 | 15 | 0.210 |
Why?
|
| Cartilage, Articular | 1 | 2007 | 416 | 0.210 |
Why?
|
| Cells, Cultured | 9 | 2019 | 524 | 0.200 |
Why?
|
| Pain Measurement | 5 | 2018 | 484 | 0.200 |
Why?
|
| Spine | 1 | 2003 | 110 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2016 | 190 | 0.200 |
Why?
|
| Chi-Square Distribution | 4 | 2016 | 138 | 0.200 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2003 | 164 | 0.200 |
Why?
|
| Prosthesis Fitting | 2 | 2020 | 21 | 0.190 |
Why?
|
| Cardiomyopathies | 1 | 2022 | 28 | 0.190 |
Why?
|
| Clinical Competence | 2 | 2021 | 210 | 0.190 |
Why?
|
| Pandemics | 2 | 2021 | 240 | 0.190 |
Why?
|
| Collagen Type I | 1 | 2021 | 19 | 0.180 |
Why?
|
| Interleukin-1beta | 7 | 2016 | 53 | 0.180 |
Why?
|
| Bone Remodeling | 1 | 2021 | 50 | 0.180 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 13 | 0.170 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2021 | 131 | 0.170 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2021 | 51 | 0.170 |
Why?
|
| Occupational Health | 1 | 2020 | 17 | 0.170 |
Why?
|
| Wounds, Penetrating | 1 | 2020 | 7 | 0.170 |
Why?
|
| Gene Expression Regulation | 3 | 2014 | 272 | 0.170 |
Why?
|
| Immunoglobulins | 1 | 2020 | 13 | 0.170 |
Why?
|
| Microscopy, Electron, Transmission | 3 | 2013 | 26 | 0.170 |
Why?
|
| Forecasting | 1 | 2020 | 92 | 0.170 |
Why?
|
| Patient Safety | 1 | 2020 | 39 | 0.170 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 482 | 0.170 |
Why?
|
| Military Personnel | 1 | 2020 | 39 | 0.160 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2019 | 9 | 0.160 |
Why?
|
| Tissue Adhesives | 1 | 2019 | 7 | 0.160 |
Why?
|
| DNA Damage | 2 | 2010 | 30 | 0.160 |
Why?
|
| Tissue Scaffolds | 1 | 2019 | 26 | 0.160 |
Why?
|
| Walking | 1 | 2021 | 252 | 0.160 |
Why?
|
| Minimally Invasive Surgical Procedures | 4 | 2007 | 316 | 0.160 |
Why?
|
| Tendons | 3 | 2006 | 222 | 0.160 |
Why?
|
| Personality Assessment | 1 | 2019 | 35 | 0.160 |
Why?
|
| Computer Simulation | 1 | 2020 | 194 | 0.160 |
Why?
|
| Range of Motion, Articular | 6 | 2016 | 708 | 0.160 |
Why?
|
| Hematopoiesis | 1 | 2018 | 11 | 0.150 |
Why?
|
| Cell Proliferation | 3 | 2010 | 179 | 0.150 |
Why?
|
| Blood Proteins | 2 | 2012 | 19 | 0.150 |
Why?
|
| Phagocytosis | 5 | 2013 | 33 | 0.150 |
Why?
|
| Sex Factors | 3 | 2017 | 467 | 0.150 |
Why?
|
| Immunity, Innate | 2 | 2021 | 65 | 0.150 |
Why?
|
| Th17 Cells | 1 | 2019 | 31 | 0.150 |
Why?
|
| Odds Ratio | 2 | 2019 | 276 | 0.150 |
Why?
|
| Joint Capsule | 1 | 2019 | 58 | 0.150 |
Why?
|
| Regenerative Medicine | 1 | 2018 | 5 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 88 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 92 | 0.150 |
Why?
|
| Bone Marrow | 1 | 2018 | 76 | 0.150 |
Why?
|
| Patient Care Bundles | 1 | 2018 | 3 | 0.150 |
Why?
|
| Risk Adjustment | 1 | 2018 | 10 | 0.150 |
Why?
|
| Oxidation-Reduction | 2 | 2015 | 65 | 0.150 |
Why?
|
| Patella | 4 | 2006 | 72 | 0.140 |
Why?
|
| Bone Resorption | 4 | 2021 | 84 | 0.140 |
Why?
|
| Knee Joint | 5 | 2007 | 754 | 0.140 |
Why?
|
| Friction | 3 | 2017 | 20 | 0.140 |
Why?
|
| Safety Management | 2 | 2020 | 13 | 0.140 |
Why?
|
| Infant, Newborn | 2 | 2021 | 582 | 0.140 |
Why?
|
| Movement | 1 | 2018 | 113 | 0.140 |
Why?
|
| Arthritis, Infectious | 1 | 2018 | 50 | 0.140 |
Why?
|
| Patient Selection | 3 | 2011 | 196 | 0.140 |
Why?
|
| Microscopy, Electron, Scanning | 5 | 2017 | 75 | 0.140 |
Why?
|
| Medicare | 1 | 2018 | 120 | 0.140 |
Why?
|
| Area Under Curve | 1 | 2017 | 64 | 0.140 |
Why?
|
| ROC Curve | 1 | 2017 | 142 | 0.130 |
Why?
|
| Young Adult | 4 | 2017 | 2022 | 0.130 |
Why?
|
| Metals, Heavy | 1 | 2016 | 6 | 0.130 |
Why?
|
| Cell Line | 4 | 2016 | 271 | 0.130 |
Why?
|
| Pain Management | 1 | 2018 | 144 | 0.130 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2016 | 37 | 0.130 |
Why?
|
| Recovery of Function | 4 | 2012 | 298 | 0.130 |
Why?
|
| Medial Collateral Ligament, Knee | 1 | 2016 | 7 | 0.130 |
Why?
|
| Synovitis | 1 | 2016 | 22 | 0.130 |
Why?
|
| Interleukin-8 | 3 | 2006 | 18 | 0.130 |
Why?
|
| Braces | 1 | 2016 | 23 | 0.130 |
Why?
|
| Arthralgia | 1 | 2017 | 133 | 0.120 |
Why?
|
| Mechanical Phenomena | 2 | 2017 | 24 | 0.120 |
Why?
|
| Dogs | 1 | 2015 | 166 | 0.120 |
Why?
|
| Interleukin-6 | 3 | 2010 | 75 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2019 | 215 | 0.120 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 66 | 0.120 |
Why?
|
| Osteoporosis | 1 | 2016 | 77 | 0.120 |
Why?
|
| Apoptosis | 2 | 2008 | 210 | 0.120 |
Why?
|
| Misonidazole | 1 | 2015 | 1 | 0.120 |
Why?
|
| Postoperative Care | 2 | 2016 | 135 | 0.120 |
Why?
|
| Intermittent Pneumatic Compression Devices | 2 | 2011 | 7 | 0.120 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2015 | 5 | 0.120 |
Why?
|
| In Vitro Techniques | 3 | 2019 | 166 | 0.120 |
Why?
|
| Placenta | 1 | 2014 | 8 | 0.120 |
Why?
|
| Phosphates | 2 | 2019 | 18 | 0.120 |
Why?
|
| Fetal Blood | 1 | 2014 | 12 | 0.120 |
Why?
|
| Hypoxia | 1 | 2015 | 32 | 0.120 |
Why?
|
| Cell Survival | 4 | 2014 | 119 | 0.120 |
Why?
|
| Glioma | 1 | 2015 | 26 | 0.120 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 88 | 0.110 |
Why?
|
| Pain | 1 | 2018 | 412 | 0.110 |
Why?
|
| Femur Head | 2 | 2023 | 69 | 0.110 |
Why?
|
| Postoperative Period | 1 | 2016 | 334 | 0.110 |
Why?
|
| Electrochemistry | 3 | 2017 | 42 | 0.110 |
Why?
|
| Adsorption | 1 | 2014 | 6 | 0.110 |
Why?
|
| Blood Sedimentation | 4 | 2016 | 53 | 0.110 |
Why?
|
| Chemokines | 3 | 2014 | 22 | 0.110 |
Why?
|
| Fibronectins | 1 | 2014 | 19 | 0.110 |
Why?
|
| Serum Albumin | 1 | 2014 | 25 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 105 | 0.110 |
Why?
|
| World Health Organization | 1 | 2013 | 9 | 0.110 |
Why?
|
| Body Mass Index | 2 | 2015 | 462 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2016 | 1896 | 0.110 |
Why?
|
| Pregnancy | 1 | 2014 | 336 | 0.110 |
Why?
|
| Neoplasms | 2 | 2009 | 239 | 0.110 |
Why?
|
| Venous Thrombosis | 2 | 2011 | 46 | 0.110 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 80 | 0.110 |
Why?
|
| Early Diagnosis | 1 | 2013 | 57 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 10 | 0.110 |
Why?
|
| Incidence | 1 | 2016 | 760 | 0.110 |
Why?
|
| Lysosomes | 1 | 2013 | 26 | 0.100 |
Why?
|
| Particulate Matter | 1 | 2013 | 18 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 34 | 0.100 |
Why?
|
| Interleukin-17 | 3 | 2021 | 18 | 0.100 |
Why?
|
| Body Fluids | 2 | 2010 | 14 | 0.100 |
Why?
|
| Anthropometry | 1 | 2012 | 31 | 0.100 |
Why?
|
| Interleukins | 1 | 2012 | 24 | 0.100 |
Why?
|
| Mice | 4 | 2021 | 1413 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 119 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 130 | 0.100 |
Why?
|
| Porosity | 3 | 2007 | 61 | 0.100 |
Why?
|
| Poisoning | 1 | 2011 | 2 | 0.100 |
Why?
|
| Flow Cytometry | 2 | 2010 | 110 | 0.090 |
Why?
|
| Osteoprotegerin | 2 | 2008 | 5 | 0.090 |
Why?
|
| RANK Ligand | 2 | 2008 | 4 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 433 | 0.090 |
Why?
|
| Treatment Failure | 2 | 2016 | 160 | 0.090 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2011 | 2 | 0.090 |
Why?
|
| Aluminum Oxide | 1 | 2011 | 7 | 0.090 |
Why?
|
| Blood Coagulation | 1 | 2011 | 21 | 0.090 |
Why?
|
| Osteoarthritis, Knee | 2 | 2006 | 373 | 0.090 |
Why?
|
| RNA, Messenger | 4 | 2007 | 310 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2011 | 56 | 0.090 |
Why?
|
| Body Size | 1 | 2010 | 11 | 0.090 |
Why?
|
| NF-kappa B | 3 | 2006 | 114 | 0.090 |
Why?
|
| Orthopedic Equipment | 1 | 2010 | 3 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2012 | 225 | 0.090 |
Why?
|
| Device Approval | 1 | 2010 | 4 | 0.090 |
Why?
|
| Spectrum Analysis | 1 | 2010 | 8 | 0.090 |
Why?
|
| Posterior Cruciate Ligament | 1 | 2010 | 23 | 0.080 |
Why?
|
| Proteins | 1 | 2010 | 63 | 0.080 |
Why?
|
| Biological Factors | 1 | 2010 | 5 | 0.080 |
Why?
|
| Bone and Bones | 2 | 2014 | 117 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 63 | 0.080 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 88 | 0.080 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 35 | 0.080 |
Why?
|
| Neutrophils | 1 | 2010 | 100 | 0.080 |
Why?
|
| Solubility | 2 | 2009 | 26 | 0.080 |
Why?
|
| Surgical Wound Infection | 1 | 2010 | 87 | 0.080 |
Why?
|
| Health Policy | 1 | 2009 | 41 | 0.080 |
Why?
|
| Necrosis | 2 | 2008 | 26 | 0.080 |
Why?
|
| Leukocyte Count | 3 | 2016 | 63 | 0.080 |
Why?
|
| Consumer Product Safety | 1 | 2009 | 5 | 0.080 |
Why?
|
| Review Literature as Topic | 1 | 2009 | 10 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 39 | 0.080 |
Why?
|
| Chromium Compounds | 1 | 2009 | 4 | 0.080 |
Why?
|
| Hydrogen | 1 | 2009 | 7 | 0.080 |
Why?
|
| Cattle | 2 | 2021 | 124 | 0.080 |
Why?
|
| C-Reactive Protein | 3 | 2016 | 96 | 0.080 |
Why?
|
| Reimbursement, Incentive | 1 | 2008 | 6 | 0.080 |
Why?
|
| Physician Incentive Plans | 1 | 2008 | 2 | 0.080 |
Why?
|
| Phagocytes | 1 | 2009 | 21 | 0.080 |
Why?
|
| Accidental Falls | 1 | 2010 | 110 | 0.080 |
Why?
|
| Polymers | 1 | 2009 | 42 | 0.080 |
Why?
|
| Vanadium | 1 | 2008 | 6 | 0.080 |
Why?
|
| Toxicity Tests | 1 | 2008 | 9 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 67 | 0.070 |
Why?
|
| Medical Laboratory Science | 1 | 2008 | 9 | 0.070 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2008 | 25 | 0.070 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 2008 | 9 | 0.070 |
Why?
|
| Trace Elements | 1 | 2007 | 4 | 0.070 |
Why?
|
| Lubrication | 1 | 2007 | 6 | 0.070 |
Why?
|
| Gamma Rays | 1 | 2007 | 15 | 0.070 |
Why?
|
| Hip Fractures | 1 | 2008 | 26 | 0.070 |
Why?
|
| Adaptation, Physiological | 1 | 2008 | 47 | 0.070 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2007 | 4 | 0.070 |
Why?
|
| Registries | 3 | 2016 | 196 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 36 | 0.070 |
Why?
|
| Osteoclasts | 2 | 2006 | 22 | 0.070 |
Why?
|
| Adaptive Immunity | 2 | 2020 | 19 | 0.070 |
Why?
|
| Osseointegration | 2 | 2007 | 67 | 0.070 |
Why?
|
| Cementation | 2 | 2021 | 32 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2008 | 110 | 0.070 |
Why?
|
| Ethics, Medical | 1 | 2006 | 7 | 0.070 |
Why?
|
| Technology Transfer | 1 | 2006 | 3 | 0.070 |
Why?
|
| Elbow Joint | 1 | 2008 | 123 | 0.070 |
Why?
|
| Research Support as Topic | 1 | 2006 | 14 | 0.060 |
Why?
|
| Chemokine CCL2 | 2 | 2006 | 21 | 0.060 |
Why?
|
| Publishing | 1 | 2006 | 34 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 332 | 0.060 |
Why?
|
| Research | 1 | 2006 | 40 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2006 | 53 | 0.060 |
Why?
|
| Equipment Design | 1 | 2006 | 139 | 0.060 |
Why?
|
| Tendon Injuries | 2 | 2005 | 203 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2021 | 83 | 0.060 |
Why?
|
| Debridement | 1 | 2006 | 100 | 0.060 |
Why?
|
| Cell Shape | 1 | 2005 | 8 | 0.060 |
Why?
|
| Chicago | 3 | 2014 | 953 | 0.060 |
Why?
|
| Oxides | 2 | 2019 | 16 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 216 | 0.060 |
Why?
|
| Electron Probe Microanalysis | 1 | 2004 | 2 | 0.060 |
Why?
|
| Histocytochemistry | 1 | 2004 | 14 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 417 | 0.060 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2005 | 75 | 0.060 |
Why?
|
| Osteocalcin | 2 | 2021 | 27 | 0.060 |
Why?
|
| Bone Cements | 3 | 2012 | 87 | 0.060 |
Why?
|
| Stainless Steel | 1 | 2003 | 16 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2003 | 49 | 0.050 |
Why?
|
| Comorbidity | 2 | 2018 | 488 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2019 | 310 | 0.050 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2003 | 4 | 0.050 |
Why?
|
| Arthroplasty | 1 | 2004 | 151 | 0.050 |
Why?
|
| Rabbits | 1 | 2003 | 180 | 0.050 |
Why?
|
| Osteoarthritis | 2 | 2005 | 330 | 0.050 |
Why?
|
| Kinetics | 1 | 2003 | 180 | 0.050 |
Why?
|
| Age Factors | 2 | 2021 | 774 | 0.050 |
Why?
|
| Equipment Failure | 1 | 2002 | 39 | 0.050 |
Why?
|
| Molecular Weight | 2 | 2014 | 26 | 0.050 |
Why?
|
| Procollagen | 1 | 2002 | 5 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2002 | 21 | 0.050 |
Why?
|
| Culture Media | 1 | 2002 | 31 | 0.050 |
Why?
|
| Motor Activity | 1 | 2005 | 321 | 0.050 |
Why?
|
| Cell Division | 1 | 2002 | 82 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2002 | 16 | 0.050 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2002 | 3 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 91 | 0.050 |
Why?
|
| Osteotomy | 1 | 2003 | 172 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2002 | 52 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2002 | 147 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 66 | 0.050 |
Why?
|
| Vitamin E | 1 | 2021 | 45 | 0.050 |
Why?
|
| Skull | 1 | 2021 | 23 | 0.050 |
Why?
|
| Immunoassay | 1 | 2021 | 38 | 0.040 |
Why?
|
| Carrier Proteins | 2 | 2013 | 98 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2021 | 82 | 0.040 |
Why?
|
| Reactive Oxygen Species | 2 | 2013 | 117 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2021 | 80 | 0.040 |
Why?
|
| Specialty Boards | 1 | 2020 | 4 | 0.040 |
Why?
|
| Finite Element Analysis | 1 | 2020 | 29 | 0.040 |
Why?
|
| Transcriptional Activation | 2 | 2013 | 31 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2021 | 117 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2013 | 78 | 0.040 |
Why?
|
| Echocardiography | 1 | 2020 | 72 | 0.040 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 33 | 0.040 |
Why?
|
| Xylenes | 1 | 2019 | 2 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2019 | 33 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 79 | 0.040 |
Why?
|
| School Admission Criteria | 1 | 2019 | 9 | 0.040 |
Why?
|
| Tissue Engineering | 1 | 2019 | 31 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2019 | 7 | 0.040 |
Why?
|
| Personnel Selection | 1 | 2019 | 21 | 0.040 |
Why?
|
| Early Ambulation | 2 | 2011 | 17 | 0.040 |
Why?
|
| Preoperative Care | 2 | 2011 | 119 | 0.040 |
Why?
|
| Mentoring | 1 | 2019 | 28 | 0.040 |
Why?
|
| Gene Expression | 2 | 2010 | 200 | 0.040 |
Why?
|
| Leadership | 1 | 2019 | 92 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2018 | 17 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 34 | 0.040 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2010 | 41 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 332 | 0.030 |
Why?
|
| Vasculitis | 1 | 2016 | 27 | 0.030 |
Why?
|
| Lipopeptides | 1 | 2016 | 10 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 94 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2016 | 259 | 0.030 |
Why?
|
| Arthroscopy | 1 | 2004 | 1091 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2015 | 28 | 0.030 |
Why?
|
| Elastic Modulus | 1 | 2014 | 10 | 0.030 |
Why?
|
| New York City | 1 | 2014 | 12 | 0.030 |
Why?
|
| Disease Management | 1 | 2015 | 105 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 892 | 0.030 |
Why?
|
| Probability | 2 | 2004 | 86 | 0.030 |
Why?
|
| Femur Neck | 1 | 2014 | 21 | 0.030 |
Why?
|
| Interferometry | 1 | 2013 | 7 | 0.030 |
Why?
|
| Electrochemical Techniques | 1 | 2013 | 8 | 0.030 |
Why?
|
| Carbon | 1 | 2013 | 9 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2013 | 21 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2005 | 279 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2014 | 41 | 0.030 |
Why?
|
| DNA | 2 | 2005 | 102 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 178 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2005 | 95 | 0.030 |
Why?
|
| Cathepsin B | 1 | 2013 | 5 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2013 | 9 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 11 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 78 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 81 | 0.030 |
Why?
|
| Disease Progression | 2 | 2006 | 673 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2013 | 11 | 0.030 |
Why?
|
| Hip Injuries | 1 | 2013 | 18 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 350 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2013 | 175 | 0.020 |
Why?
|
| New Zealand | 1 | 2011 | 11 | 0.020 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2011 | 9 | 0.020 |
Why?
|
| International Cooperation | 1 | 2011 | 15 | 0.020 |
Why?
|
| Australia | 1 | 2011 | 40 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2011 | 15 | 0.020 |
Why?
|
| Vena Cava Filters | 1 | 2011 | 8 | 0.020 |
Why?
|
| United Kingdom | 1 | 2011 | 49 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2002 | 107 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 256 | 0.020 |
Why?
|
| Anesthesia, Epidural | 1 | 2011 | 19 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2011 | 56 | 0.020 |
Why?
|
| Joint Instability | 1 | 2016 | 393 | 0.020 |
Why?
|
| Hemophilia A | 1 | 2011 | 49 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 399 | 0.020 |
Why?
|
| Reducing Agents | 1 | 2010 | 3 | 0.020 |
Why?
|
| Free Radicals | 1 | 2010 | 8 | 0.020 |
Why?
|
| Pedigree | 1 | 2011 | 55 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2010 | 2 | 0.020 |
Why?
|
| B7-1 Antigen | 1 | 2010 | 5 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 13 | 0.020 |
Why?
|
| Polymethacrylic Acids | 1 | 2010 | 5 | 0.020 |
Why?
|
| Marketing | 1 | 2010 | 3 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2010 | 29 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 317 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 2010 | 51 | 0.020 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2011 | 84 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2011 | 89 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 142 | 0.020 |
Why?
|
| Phenotype | 1 | 2011 | 312 | 0.020 |
Why?
|
| NADP | 1 | 2009 | 9 | 0.020 |
Why?
|
| Illinois | 1 | 2010 | 252 | 0.020 |
Why?
|
| X-Ray Diffraction | 1 | 2009 | 13 | 0.020 |
Why?
|
| Patellofemoral Joint | 1 | 2010 | 66 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 366 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2008 | 10 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 292 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2008 | 20 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 101 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 678 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2007 | 34 | 0.020 |
Why?
|
| Arthritis | 1 | 2008 | 52 | 0.020 |
Why?
|
| Connective Tissue | 1 | 2007 | 25 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2006 | 2 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2006 | 19 | 0.020 |
Why?
|
| Cytochalasin D | 1 | 2006 | 5 | 0.020 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2006 | 5 | 0.020 |
Why?
|
| Supine Position | 1 | 2006 | 21 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 1155 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2005 | 18 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2008 | 258 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2005 | 37 | 0.010 |
Why?
|
| Rupture | 1 | 2004 | 109 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 264 | 0.010 |
Why?
|
| Physical Therapy Modalities | 1 | 2004 | 74 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 260 | 0.010 |
Why?
|
| Exercise Test | 1 | 2005 | 123 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2003 | 29 | 0.010 |
Why?
|
| Exercise | 1 | 2007 | 453 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 305 | 0.010 |
Why?
|
| Trauma Severity Indices | 1 | 2002 | 10 | 0.010 |
Why?
|
| Amino Acids | 1 | 2002 | 20 | 0.010 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2002 | 1 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2002 | 6 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2002 | 12 | 0.010 |
Why?
|
| Glycosylation | 1 | 2002 | 20 | 0.010 |
Why?
|
| Tyrosine | 1 | 2002 | 23 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 129 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 106 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 148 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 144 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 192 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 117 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2002 | 89 | 0.010 |
Why?
|
| Osteogenesis | 1 | 2002 | 107 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2002 | 589 | 0.010 |
Why?
|